News | July 04, 2025
argenx advances clinical development of agonist antibody for myasthenic syndromes
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability
Prucalopride Tablets are indicated for the treatment of chronic idiopathic constipation in adults
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Subscribe To Our Newsletter & Stay Updated
